- » Primary Immunogenicity and Safety objectives met » All formulations of V710 were immunogenic following a single or two-dose application ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Research & Development Subtitle: – » Primary Immunogenicity and Safety objectives met » All formulations [...]
Tag Archive > Dose Regimen
Tolerx Completes Enrollment in DEFEND-1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
Cambridge, Massachusetts (ots/PRNewswire) – Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes. The DEFEND-1 (Durable Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) [...]
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Paris, and Princeton, New Jersey (ots/PRNewswire) – -No added benefit on the composite primary end-point with the higher dose when entire ACS study population considered- -Important new findings with higher loading dose of PLAVIX(R) for heart patients undergoing coronary angioplasty (PCI)- Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical [...]
EANS-Adhoc: Intercell AG / Intercell AG Announces First Subject Enrolled in a Phase II Trial for the further development of its investigational Vaccine Enhancement Patch to improve Pandemic Influenza prevention in Collaboration with U.S. Department of He
——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Research & Development 28.05.2009 » Phase II clinical trial investigating the effectiveness of Intercell´s Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today [...]
